Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of PF-07059013 in Healthy Adults
NCT04323124Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07059013 in sickle cell disease (SCD) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Event(s) at 10 weeks, Number of Participants With Laboratory Test Findings of Potential Clinical Importance at Day 21 and 2 more. Started Jul 2020; status: terminated.
02
Drugs
PF-07059013
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04323124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323124.